Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

61. Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis

Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis 28756575 2018 11 13 2199-1154 4 3 2017 Sep Drugs - real world outcomes Drugs Real World Outcomes Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis. 139-149 10.1007/s40801-017-0114-9 Regulatory agencies often request prospective, product-specific post-authorization pregnancy exposure (...) registries to monitor safety during pregnancy, even though studies using existing health databases could also be employed. Using multiple sclerosis (MS) as a case study, we evaluated various study designs and data sources previously used to study medication exposure in pregnancy. We examined (1) strengths and limitations of study designs used for pregnancy safety studies in women exposed to MS-specific medications during pregnancy and (2) existing data sources used to conduct such studies in other

Drugs - real world outcomes2017 Full Text: Link to full Text with Trip Pro

62. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial

Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial 28894553 2018 11 13 2008-5842 9 7 2017 Jul Electronic physician Electron Physician Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial. 4899-4905 10.19082/4899 Multiple Sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system. Oxidative stress plays (...) a major role in the onset and progression of MS. Asymmetric dimethylarginine (ADMA) formation is dependent on oxidative stress status. We examined whether alpha-lipoic acid (ALA) as a potent antioxidant could improve the Expanded Disability Status Scale (EDSS) and decrease plasma level of ADMA in multiple sclerosis patients. In a randomized, double-blinded clinical trial conducted at Sina Hospital in Tehran, Iran, from September 2009 to July 2011, 24 patients with relapsing-remitting MS were divided

Electronic physician2017 Full Text: Link to full Text with Trip Pro

63. Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years)

Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) July 2017 Technology Description: The current treatment is already licensed in adults (...) , but is currently in a phase III trial for the treatment of multiple sclerosis in paediatric patients. Fingolimod will be administered orally once daily at a dose of either 0.5 mg or 0.25 mg depending on the patient’s body weight. If marketed this will become the first treatment with a specific licensed indication for paediatric multiple sclerosis. Specialty You may also be interested in: Apr 2015 Specialty: Apr 2015 Specialty: Apr 2015 Specialty: Please answer these 2 questions to proceed to your free download

NIHR Innovation Observatory2017

64. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial 28600189 2017 06 10 2017 06 10 1474-4465 2017 Jun 06 The Lancet. Neurology Lancet Neurol Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS (...) -STAT randomised, placebo-controlled trial. S1474-4422(17)30113-8 10.1016/S1474-4422(17)30113-8 In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

65. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]

[Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe

Health Technology Assessment (HTA) Database.2017

66. Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression

Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression 28602542 2017 06 12 2017 06 12 1873-2607 2017 Jun 08 American journal of preventive medicine Am J Prev Med Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression. S0749-3797(17)30246-5 10.1016/j.amepre.2017.04.011 This study examined the extent to which patient and trial characteristics moderate the effects of exercise on depressive symptoms among people (...) with multiple sclerosis. Twenty-four effects were derived from 14 articles published before August 2016 located using Google Scholar, MEDLINE, PsycINFO, PubMed, and Web of Science. Trials involved 624 people with multiple sclerosis and included both randomization to exercise training or a non-exercise control condition and measurement of depressive symptoms at baseline and at mid- and/or post-intervention. Hedges' d effect sizes were computed, study quality was assessed, and random effects models were used for all

EvidenceUpdates2017

67. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. BACKGROUND: On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated syndrome) to multiple sclerosis. METHODS: During the period from January 2009 through July 2013, we randomly assigned participants who had had their first demyelinating symptoms (...) within the previous 180 days to receive either 100 mg of minocycline, administered orally twice daily, or placebo. Administration of minocycline or placebo was continued until a diagnosis of multiple sclerosis was established or until 24 months after randomization, whichever came first. The primary outcome was conversion to multiple sclerosis (diagnosed on the basis of the 2005 McDonald criteria) within 6 months after randomization. Secondary outcomes included conversion to multiple sclerosis within

NEJM2017

68. Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis

Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis Ocrevus (ocrelizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Ocrevus (ocrelizumab) Injection Ocrevus Company: Genentech, Inc. Application No.: 761053 Approval Date: 03/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2017

69. Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy

Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy - GOV.UK GOV.UK uses cookies to make the site simpler. Search Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy From: Published: 24 April 2017 Therapeutic area: Healthcare professionals should report any suspected adverse effects relating to fingolimod (Gilenya▼) or other (...) treatments for multiple sclerosis, including suspected adverse effects occurring after discontinuation, via the Yellow Card Scheme. We are aware of two recently published articles describing a suspected rebound syndrome (clinical and radiological signs of severe exacerbation beyond what was expected for that patient prior to discontinuation or treatment change) in patients with multiple sclerosis after treatment with fingolimod (Gilenya▼) was stopped, some of whom were switched to other treatments

MHRA Drug Safety Update2017

70. Daclizumab for treating relapsing?remitting multiple sclerosis

Daclizumab for treating relapsing?remitting multiple sclerosis Daclizumab for treating relapsing–remitting multiple sclerosis | Guidance and guidelines | NICE Daclizumab for treating relapsing–remitting multiple sclerosis Technology appraisal guidance [TA441] Published date: 26 April 2017 Guidance This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s . Explore © NICE [year]. All rights reserved. Subject to .

National Institute for Health and Clinical Excellence - Technology Appraisals2017

71. Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions

Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions 28607651 2018 11 13 2008-5842 9 4 2017 Apr Electronic physician Electron Physician Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions. 4162-4170 10.19082/4162 Multiple sclerosis (MS) is a demyelinating disease of the central (...) nervous system. MRI has an important role in early diagnosis of MS within diagnostic criteria. To determine the diagnostic value of the double inversion recovery (DIR) sequence in detection of brain MS lesions. In this cross-sectional study, 55 patients were admitted to the MRI department in Vali-E-Asr Hospital in Qaemshahr, Iran, from May 2016 to February 2016. Imaging was performed on a 1.5T Philips MR system using DIR, fluid attenuated inversion recovery (FLAIR), and T2-weighted turbo spin echo (T2W_TSE

Electronic physician2017 Full Text: Link to full Text with Trip Pro

73. Multiple Sclerosis

Multiple Sclerosis ©Institute for Clinical and Economic Review, 2017 Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Final Evidence Report March 6, 2017 Prepared for ©Institute for Clinical and Economic Review, 2017 Page i Final Evidence Report – DMTs for RRMS and PPMS ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group Jeffrey A. Tice, MD Professor of Medicine University of California (...) , San Francisco Rick Chapman, PhD, MS Director of Health Economics Institute for Clinical and Economic Review Varun Kumar, MBBS, MPH, MSc Health Economist Institute for Clinical and Economic Review Anne M. Loos, MA Senior Research Associate Institute for Clinical and Economic Review Shanshan Liu, MS, MPH Research Associate Institute for Clinical and Economic Review Matt Seidner, BS Program Manager Institute for Clinical and Economic Review Daniel A. Ollendorf, PhD Chief Scientific Officer Institute

California Technology Assessment Forum2017

74. Portable neuromodulation stimulator for multiple sclerosis

Portable neuromodulation stimulator for multiple sclerosis Portable neuromodulation stimulator for multiple sclerosis ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Portable neuromodulation stimulator for multiple sclerosis March 2017 Technology Description: The Portable Neuromodulation Stimulator or PoNS™, developed by Helius Medical Technologies, is a non-invasive device that is designed to deliver neurostimulation through the tongue to improve balance (...) and gait in patients with advanced multiple sclerosis (MS). The device is intended to be used as part of targeted functional therapy called Cranial Nerve Non-Invasive Neuromodulation (CN-NINM) in combination with rehabilitation. The PoNS™ is placed on the tongue, where it painlessly stimulates the tongue with electrical pulses. Stimulation of the trigeminal and facial nerves from the tongue delivers electrical signals directly into the brain stem and from there to the rest of the brain. The electrical

NIHR Innovation Observatory2017

75. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study.

Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. BACKGROUND: Emerging evidence suggests that living near major roads might adversely affect cognition. However, little is known about its relationship with the incidence of dementia, Parkinson's disease, and multiple sclerosis. We aimed to investigate the association between residential proximity to major roadways and the incidence of these three neurological (...) diseases in Ontario, Canada. METHODS: In this population-based cohort study, we assembled two population-based cohorts including all adults aged 20-50 years (about 4·4 million; multiple sclerosis cohort) and all adults aged 55-85 years (about 2·2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Canada on April 1, 2001. Eligible patients were free of these neurological diseases, Ontario residents for 5 years or longer, and Canadian-born. We ascertained the individual's proximity

Lancet2017

76. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Early, active multiple sclerosis lesions show four immunopathological patterns of demyelination. Although these patterns differ between patients, multiple active lesions from a given patient have an identical pattern, which suggests pathogenic heterogeneity. Therapeutic plasma exchange (TPE) has been successfully used to treat fulminant demyelinating attacks unresponsive to steroids (...) improvement after TPE (p<0.0001). Patients with multiple sclerosis with pattern II pathology are more likely to respond favourably to TPE than are patients with patterns I or III.

Lancet2017

77. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. BACKGROUND: Neuromyelitis optica is an inflammatory demyelinating disease with generally poor prognosis that selectively targets optic nerves and spinal cord. It is commonly misdiagnosed as multiple sclerosis. Neither disease has a distinguishing biomarker, but optimum treatments differ. The relation of neuromyelitis optica to optic-spinal multiple sclerosis in Asia is uncertain. We assessed the capacity (...) of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple sclerosis. METHODS: Indirect immunofluorescence with a composite substrate of mouse tissues identified a distinctive NMO-IgG staining pattern, which we characterised further by dual immunostaining. We tested masked serum samples from 102 North American patients with neuromyelitis optica or with syndromes that suggest high risk of the disorder, and 12 Japanese patients with optic

Lancet2017